Home/Pipeline/Antibody Therapeutics (SARS-CoV-2)

Antibody Therapeutics (SARS-CoV-2)

COVID-19

Discovery/PreclinicalActive

Key Facts

Indication

COVID-19

Phase

Discovery/Preclinical

Status

Active

Company

Adaptive Biotechnologies

About Adaptive Biotechnologies

Adaptive Biotechnologies is a commercial-stage company on a mission to harness the adaptive immune system as a natural diagnostic and therapeutic tool. Its core achievement is the development of the Immune Medicine Platform, which sequences and maps immune receptors at scale, enabling both its growing clonoSEQ MRD diagnostics business and a deep drug discovery pipeline. The company's strategy is to leverage its unique, data-generating platform to create a sustainable competitive moat across both diagnostics and therapeutics, aiming to transform the detection, monitoring, and treatment of disease.

View full company profile

Therapeutic Areas

Oncology Autoimmune Diseases Infectious Diseases Neurodegenerative Disorders

Other COVID-19 Drugs

Drug	Company	Phase	Status
COVID-19 Severity Prediction Test	Age Labs	Development	Active
PanCytoVir™ (oral probenecid)	TrippBio	Phase 2	Active
OT-101	Sapu BioScience	Clinical Trial (Phase not specified)	Active
Idylla SARS-CoV-2 Test	Biocartis	Approved	CE-IVD
COVID-19 Vaccine Testing (for AstraZeneca)	Advaxia Biologics	Approved	Active
COVID-19 Vaccine Clinical Batches	Advaxia Biologics	Clinical	Active
UOL COVID-19 Test	Uh-Oh Labs	Approved	Active
Lagevrio (molnupiravir)	Ridgeback Biotherapeutics	Approved/EUA	Active
CVXGA	CyanVac	Phase 2	Active
SARS-CoV-2 Test	NanoPin Technologies	Commercial (LDT)	Active
Emeramide for COVID-19	EmeraMed	Preclinical	Active
COVID-19 Oral Therapeutic (with Sen-Jam Pharmaceutical)	KVK Tech	Development	Active